Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma. Read more about Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma.
The long non-coding RNA HOTAIR is transcriptionally activated by HOXA9 and is an independent prognostic marker in patients with malignant glioma. Read more about The long non-coding RNA HOTAIR is transcriptionally activated by HOXA9 and is an independent prognostic marker in patients with malignant glioma.
Preclinical characterization of therapeutic antibodies targeted at the carboxy-terminus of Sonic hedgehog. Read more about Preclinical characterization of therapeutic antibodies targeted at the carboxy-terminus of Sonic hedgehog.
Old Sonic Hedgehog, new tricks: a new paradigm in thoracic malignancies. Read more about Old Sonic Hedgehog, new tricks: a new paradigm in thoracic malignancies.
Mutational landscape of radiation-associated angiosarcoma of the breast. Read more about Mutational landscape of radiation-associated angiosarcoma of the breast.
Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer. Read more about Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer.
Single-cell RNA sequencing reveals gene expression signatures of breast cancer-associated endothelial cells. Read more about Single-cell RNA sequencing reveals gene expression signatures of breast cancer-associated endothelial cells.
Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels. Read more about Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels.
HDAC inhibition potentiates immunotherapy in triple negative breast cancer. Read more about HDAC inhibition potentiates immunotherapy in triple negative breast cancer.
Personalized therapy: CNS HGNET-BCOR responsiveness to arsenic trioxide combined with radiotherapy. Read more about Personalized therapy: CNS HGNET-BCOR responsiveness to arsenic trioxide combined with radiotherapy.
